Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

75.08 +1.72 (+2.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in platinum-resistant ovarian cancer. 
Via Benzinga
Why Is Corcept (CORT) Stock Soaring Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Monday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Earnings Scheduled For February 26, 2025
Via Benzinga
Exploring NASDAQ:CORT's high growth characteristics.
Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) suited for high growth investing? 
Via Chartmill
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout.
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a strong growth stock, setting up for a breakout. 
Via Chartmill
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Monday's pre-market session: top gainers and losers
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
NASDAQ:CORT is not too expensive for the growth it is showing.
For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. 
Via Chartmill
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 Reasons to Sell CORT and 1 Stock to Buy Instead
Corcept currently trades at $58.76 and has been a dream stock for shareholders. It’s returned 434% since March 2020, blowing past the S&P 500’s 117% gain. The company has also beaten the index over the... 
Via StockStory
Topics Stocks
Exposures US Equities
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued.
Uncover the potential of CORCEPT THERAPEUTICS INC, a growth stock reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive... 
Via Chartmill
3 Growth Stocks in Hot Water
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
1 Small-Cap Stock on Our Buy List and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension
From Corcept Therapeutics Incorporated
Via Business Wire
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
Why Corcept (CORT) Shares Are Sliding Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.3% in the pre-market session after the company reported weak fourth quarter results: its revenue missed significantly, and its EPS... 
Via StockStory
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q4 Earnings
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics
Via Business Wire
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.
CORCEPT THERAPEUTICS INC was identified as an affordable growth stock. NASDAQ:CORT is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably. 
Via Chartmill
Corcept (CORT) Q4 Earnings Report Preview: What To Look For
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results tomorrow afternoon. Here’s what you need to know. 
Via StockStory
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
Looking for growth without the hefty price tag? Consider NASDAQ:CORT.
CORCEPT THERAPEUTICS INC could be undervalued. NASDAQ:CORT is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback